Press release
KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET.\n\nA live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be available on KalVista’s website for 30 days following the presentation.\n\nAbout KalVista Pharmaceuticals, Inc.\n\nKalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.\n\nFor more information, please visit www.kalvista.com.\n\nForward-Looking Statements\n\nThis press release contains \"forward-looking\" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: \"anticipate,\" \"intend,\" \"plan,\" \"goal,\" \"seek,\" \"believe,\" \"project,\" \"estimate,\" \"expect,\" \"strategy,\" \"future,\" \"likely,\" \"may,\" \"should,\" \"will\" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examp...